Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HX008 plus irinotecan versus placebo plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer
CTR20201055Phase 3Active
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pucotenlimab, irinotecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Taizhou Hanzhong Biomedical. Started Sep 2020; status: active.
02
Drugs
pucotenlimabirinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20201055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201055.